Rui Amaral Mendes

Prof. Rui Amaral Mendes

MEDCIDS, Faculty of Medicine of University of Porto, Porto, Portugal
orcid
PhD, FIAOMS, FIAOO, MASCO

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NYNoam Yarom
Noam Yarom
CSCharles L. Shapiro
Charles L. Shapiro
DPDouglas E. Peterson
Douglas E. Peterson
CPCatherine H. Van Poznak
Catherine H. Van Poznak
KBKari Bohlke
Kari Bohlke
DSDeborah P. Saunders
Deborah P. Saunders
PURPOSE: To provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer.METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. Guideline development involved a systematic review of the literature and a formal consensus process. PubMed and EMBASE were searched for studies of the prevention and management of MRONJ related to bone-modifying agents (BMAs) for oncologic indications published between January 2009 and December 2017. Results from an earlier systematic review (2003 to 2008) were also included.RESULTS: The systematic review identified 132 publications, only 10 of which were randomized controlled trials. Recommendations underwent two rounds of consensus voting.RECOMMENDATIONS: Currently, MRONJ is defined by (1) current or previous treatment with a BMA or angiogenic inhibitor, (2) exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region and that has persisted for longer than 8 weeks, and (3) no history of radiation therapy to the jaws or metastatic disease to the jaws. In patients who initiate a BMA, preventive care includes comprehensive dental assessments, discussion of modifiable risk factors, and avoidance of elective dentoalveolar surgery (ie, surgery that involves the teeth or contiguous alveolar bone) during BMA treatment. It remains uncertain whether BMAs should be discontinued before dentoalveolar surgery. Staging of MRONJ should be performed by a clinician with experience in the management of MRONJ. Conservative measures comprise the initial approach to MRONJ treatment. Ongoing collaboration among the dentist, dental specialist, and oncologist is essential to optimal patient care.

1 February 2019 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Open access
Nicolatou-galitis OuraniaNicolatou-galitis Ourania
Nicolatou-galitis Ourania
MSMorten Schiødt
Morten Schiødt
Rui Amaral MendesRui Amaral Mendes
Rui Amaral Mendes
CRCarla Ripamonti
Carla Ripamonti
SHSally Hope
Sally Hope
TWTim Van Den Wyngaert
Tim Van Den Wyngaert
Skeletal complications caused by osteoporosis or bone metastases are associated with considerable pain, increased mortality, and reduced quality of life. Furthermore, such events place a burden on health care resources. Agents that prevent bone resorption, such as bisphosphonates or denosumab, can reduce the risk of skeletal-related events and are widely used in patients with osteoporosis or bone metastases of cancer. Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but potentially serious, adverse event associated with high cumulative doses of bisphosphonates or denosumab. However, MRONJ can be treated, and the likelihood of the development of this condition can be reduced through prophylactic dental care and the maintenance of good oral hygiene. Dentists, as part of a multiprofessional team, have a critical role in preventing MRONJ. This review describes the incidence and pathophysiology of MRONJ and provides guidance for dental practitioners with regard to the screening, prophylactic treatment, diagnosis, and management of patients with this condition.

11 May 2020 in European Journal of Dental Education
Verified
Journal Article
Open access
PDF file
Barry F.A. QuinnBarry F.A. Quinn
Barry F.A. Quinn
JFJames Field
James Field
RGRonald Gorter
Ronald Gorter
IAIlze Akota
Ilze Akota
MCMaria Cristina Manzanares Céspedes
Maria Cristina Manzanares Céspedes
STStéphanie Tubert‐Jeannin
Stéphanie Tubert‐Jeannin
The COVID‐19 pandemic has had an immediate and dramatic impact on dental education. The Association of Dental Education in Europe decided to carry out an investigation to assess the immediate response of European Academic Dental Institutions. An online survey was sent to both member and non‐member dental schools to investigate the impact on non‐clinical and clinical education, assessment and the well‐being/pastoral care measures implemented. The preliminary findings and discussion are presented in this paper, for the responses collected between the 25 March and 5 April 2020. The survey at this time of publication is ongoing, and detailed results can be accessed https://adee.org/covid‐19‐european‐dental‐education%E2%80%99s‐immediate‐response.

1 April 2010 in Oral Oncology
Verified
Journal Article
Closed access
Rui Amaral MendesRui Amaral Mendes
Rui Amaral Mendes
JCJoão F.C. Carvalho
João F.C. Carvalho
IWIsaac van der Waal
Isaac van der Waal

8 March 2011 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
MLMw Lingen
Mw Lingen
APA Pinto
A Pinto
Rui Amaral MendesRui Amaral Mendes
Rui Amaral Mendes
RFR Franchini
R Franchini
RCR Czerninski
R Czerninski
SWS‐B Woo
S‐B Woo

1 August 2016 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Closed access
Pia Lopez-JornetPia Lopez-Jornet
Pia Lopez-Jornet
APArturo Sanchez Perez
Arturo Sanchez Perez
Rui Amaral MendesRui Amaral Mendes
Rui Amaral Mendes
Aurelio TobiasAurelio Tobias
Aurelio Tobias